Patents Represented by Attorney Shelley P. M. Fussey
  • Patent number: 8137540
    Abstract: Disclosed are improved methods and apparatus for radiolabeling, particularly methods and apparatus for large scale in-line radiolabeling of products, such as proteins and antibodies.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: March 20, 2012
    Assignee: Peregrine Pharmaceuticals, Inc.
    Inventors: Raimo Pellikka, Steven W. King, Peter Bläuenstein, Pius A. Schubiger
  • Patent number: 7976868
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: July 12, 2011
    Assignee: Board of Regents, The University of Texas System
    Inventor: Philip E. Thorpe
  • Patent number: 7951356
    Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: May 31, 2011
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Steven W. King, Boning Gao
  • Patent number: 7879801
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: February 1, 2011
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Jin He
  • Patent number: 7790860
    Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidyserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: September 7, 2010
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
  • Patent number: 7790159
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: September 7, 2010
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, M. Melina Soares, Sophia Ran
  • Patent number: 7714109
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: May 11, 2010
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Xianming Huang, Sophia Ran
  • Patent number: 7691380
    Abstract: Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: April 6, 2010
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Thomas S. Edgington
  • Patent number: 7678386
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: March 16, 2010
    Assignee: Board of Regents the University of Texas
    Inventors: Philip E. Thorpe, Xianming Huang, Sophia Ran
  • Patent number: 7625563
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: December 1, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Sophia Ran
  • Patent number: 7622118
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: November 24, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Sophia Ran
  • Patent number: 7615223
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: November 10, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Sophia Ran
  • Patent number: 7611704
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: November 3, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, M. Melina Soares, Sophia Ran
  • Patent number: 7591953
    Abstract: Disclosed are improved methods and apparatus for radiolabeling, particularly methods and apparatus for large scale in-line radiolabeling of products, such as proteins and antibodies.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: September 22, 2009
    Assignee: Peregrine Pharmaceuticals, Inc.
    Inventors: Raimo Pellikka, Steven W. King, Peter Bläuenstein, Pius A. Schubiger
  • Patent number: 7572442
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: July 15, 2003
    Date of Patent: August 11, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Sophia Ran
  • Patent number: 7572448
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: August 11, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Xianming Huang, Sophia Ran
  • Patent number: 7550141
    Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: June 23, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
  • Patent number: 7511124
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: March 31, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, M. Melina Soares, Jin He
  • Patent number: 7455833
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: November 25, 2008
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, M. Melina Soares, Sophia Ran
  • Patent number: 7422738
    Abstract: Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: September 9, 2008
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Sophia Ran